TY - JOUR
T1 - CRISPR/Cas9 system in breast cancer therapy
T2 - advancement, limitations and future scope
AU - Karn, Vamika
AU - Sandhya, Sandhya
AU - Hsu, Wayne
AU - Parashar, Deepak
AU - Singh, Himanshu Narayan
AU - Jha, Niraj Kumar
AU - Gupta, Saurabh
AU - Dubey, Navneet Kumar
AU - Kumar, Sanjay
N1 - Funding Information:
SK is highly grateful to Sharda University, Greater Noida, UP, India, and MTA Infotech for all resources for this work.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Cancer is one of the major causes of mortality worldwide, therefore it is considered a major health concern. Breast cancer is the most frequent type of cancer which affects women on a global scale. Various current treatment strategies have been implicated for breast cancer therapy that includes surgical removal, radiation therapy, hormonal therapy, chemotherapy, and targeted biological therapy. However, constant effort is being made to introduce novel therapies with minimal toxicity. Gene therapy is one of the promising tools, to rectify defective genes and cure various cancers. In recent years, a novel genome engineering technology, namely the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein-9 (Cas9) has emerged as a gene-editing tool and transformed genome-editing techniques in a wide range of biological domains including human cancer research and gene therapy. This could be attributed to its versatile characteristics such as high specificity, precision, time-saving and cost-effective methodologies with minimal risk. In the present review, we highlight the role of CRISPR/Cas9 as a targeted therapy to tackle drug resistance, improve immunotherapy for breast cancer.
AB - Cancer is one of the major causes of mortality worldwide, therefore it is considered a major health concern. Breast cancer is the most frequent type of cancer which affects women on a global scale. Various current treatment strategies have been implicated for breast cancer therapy that includes surgical removal, radiation therapy, hormonal therapy, chemotherapy, and targeted biological therapy. However, constant effort is being made to introduce novel therapies with minimal toxicity. Gene therapy is one of the promising tools, to rectify defective genes and cure various cancers. In recent years, a novel genome engineering technology, namely the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein-9 (Cas9) has emerged as a gene-editing tool and transformed genome-editing techniques in a wide range of biological domains including human cancer research and gene therapy. This could be attributed to its versatile characteristics such as high specificity, precision, time-saving and cost-effective methodologies with minimal risk. In the present review, we highlight the role of CRISPR/Cas9 as a targeted therapy to tackle drug resistance, improve immunotherapy for breast cancer.
KW - Breast cancer
KW - CRISPR/Cas9
KW - Diagnosis
KW - Drug resistance
KW - Gene editing
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85134723611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134723611&partnerID=8YFLogxK
U2 - 10.1186/s12935-022-02654-3
DO - 10.1186/s12935-022-02654-3
M3 - Review article
AN - SCOPUS:85134723611
SN - 1475-2867
VL - 22
JO - Cancer Cell International
JF - Cancer Cell International
IS - 1
M1 - 234
ER -